Arcellx (ACLX) Research & Development (2021 - 2025)
Arcellx (ACLX) recorded quarterly Research & Development of $34.1 million in Q4 2025, down 2.83% quarter-over-quarter from $35.1 million in Q3 2025, and down 23.64% on a YoY basis from $44.6 million in Q4 2024.
Arcellx (ACLX) Research & Development (2021 - 2025) Analysis & Trends
Arcellx's Research & Development history runs 5 years deep, the most recent figure standing at $34.1 million for Q4 2025.
- In Q4 2025, Research & Development fell 23.64% year-over-year to $34.1 million; the TTM figure through Dec 2025 stood at $157.6 million (changed 0.33% YoY), while the FY2025 annual figure was $157.6 million, changed 0.33% from the prior year.
- Research & Development was $34.1 million for Q4 2025 at Arcellx, down from $35.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $83.5 million in Q3 2022 to a low of $8.5 million in Q1 2021.
- Historically, Research & Development has averaged $32.2 million across 5 years, with a median of $32.6 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Research & Development soared 577.27% in 2022, then slumped 47.52% in 2023.
- A 5-year view of Research & Development shows it stood at $13.4 million in 2021, then jumped by 93.69% to $25.9 million in 2022, then climbed by 10.95% to $28.8 million in 2023, then soared by 55.12% to $44.6 million in 2024, then decreased by 23.64% to $34.1 million in 2025.
- The last three Research & Development figures came in at $34.1 million (Q4 2025), $35.1 million (Q3 2025), and $37.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 34.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.10 Mn |
| Sep 30, 2025 | 35.09 Mn |
| Jun 30, 2025 | 37.63 Mn |
| Mar 31, 2025 | 50.80 Mn |
| Dec 31, 2024 | 44.65 Mn |
| Sep 30, 2024 | 39.17 Mn |
| Jun 30, 2024 | 40.95 Mn |
| Mar 31, 2024 | 32.32 Mn |
| Dec 31, 2023 | 28.78 Mn |
| Sep 30, 2023 | 43.81 Mn |
| Jun 30, 2023 | 28.33 Mn |
| Mar 31, 2023 | 32.93 Mn |
| Dec 31, 2022 | 25.94 Mn |
| Sep 30, 2022 | 83.47 Mn |
| Jun 30, 2022 | 22.08 Mn |
| Mar 31, 2022 | 18.06 Mn |
| Dec 31, 2021 | 13.39 Mn |
| Sep 30, 2021 | 12.33 Mn |
| Jun 30, 2021 | 12.64 Mn |
| Mar 31, 2021 | 8.52 Mn |